• Explore /
  • Poster
  • / Phase 1 trial of first-line bintrafusp alfa in combination with other anticancer therapies in patients (pts) with locally advanced or advanced cervical cancer.

Phase 1 trial of first-line bintrafusp alfa in combination with other anticancer therapies in patients (pts) with locally advanced or advanced cervical cancer.

Abstract Poster

Authors

Ana Oaknin

Ana Oaknin

Vall d'Hebron Institute of Oncology, Hospital Universitari Vall d’Hebron, and Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain

Ana Oaknin , Sharad A. Ghamande , Yuka Kasamatsu , Marta Gil-Martin , Elisabeth J. Diver , Genevieve Jehl , Stephan A. Gleicher , Surendra Chaudhary , Yulia Vugmeyster , Kosei Hasegawa

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gynecologic Cancer

Track

Gynecologic Cancer

Sub Track

Cervical Cancer

Clinical Trial Registration Number

NCT04551950

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 5528)

DOI

10.1200/JCO.2022.40.16_suppl.5528

Abstract #

5528

Poster Bd #

407

Abstract Disclosures

Similar Posters

First Author: Jianqing Zhu

Poster

2023 ASCO Gastrointestinal Cancers Symposium

Phase 1 trial of the anti-LAG3 antibody favezelimab plus pembrolizumab in advanced gastric cancer.

Phase 1 trial of the anti-LAG3 antibody favezelimab plus pembrolizumab in advanced gastric cancer.

First Author: Sun Young Rha

First Author: Xiaoyun Pan

First Author: Ronnie Shapira-Frommer